Nath Bio-Genes Reports Strong Q1 FY2026 Results with 12.7% Profit Growth
Nath Bio-Genes (India) Limited announced strong Q1 FY2026 results with revenue increasing 14.9% to ₹280.17 crore and net profit rising 12.7% to ₹38.21 crore compared to the same period last year. Operating profit grew 4.7% to ₹37.93 crore. The company's Board approved the appointment of Ms. Payal Jain as an Additional Director, pending shareholder approval for her role as Independent Director.
*this image is generated using AI for illustrative purposes only.
Nath Bio-Genes (India) Limited, a leading player in the seed industry, has announced its financial results for the first quarter of the fiscal year 2025-26, showcasing robust growth in both revenue and profitability.
Financial Highlights
- Revenue Growth: The company reported a significant increase in revenue for Q1 FY2026, rising to ₹280.17 crore from ₹243.88 crore in the same period last year, marking a 14.9% year-over-year growth.
- Profit Surge: Net profit for the quarter stood at ₹38.21 crore, up from ₹33.89 crore in Q1 of the previous fiscal year, representing a 12.7% increase.
- Operating Performance: Nath Bio-Genes demonstrated strong operational efficiency, with profit from operations before other income, finance cost, and exceptional items reaching ₹37.93 crore, compared to ₹36.23 crore in the corresponding quarter of the previous year.
Key Financial Metrics
| Particulars (₹ in crore) | Q1 FY2026 | Q1 FY2025 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 280.17 | 243.88 | +14.9% |
| Net Profit | 38.21 | 33.89 | +12.7% |
| Operating Profit | 37.93 | 36.23 | +4.7% |
Management Commentary
While specific management comments were not provided, the strong financial performance reflects the company's continued focus on growth and operational excellence in the competitive seed industry.
Board Meeting Outcomes
In addition to approving the financial results, the Board of Directors, at its meeting held on July 11, 2025, made the following key decision:
- New Independent Director: The Board approved the appointment of Ms. Payal Jain as an Additional Director (to be appointed as Independent Director subject to shareholder approval at the upcoming Annual General Meeting).
About Ms. Payal Jain
Ms. Payal Jain brings over 15 years of professional experience to the board, including:
- Expertise in sales, negotiations, business development, and project management
- 5 years of experience in real estate
- Currently serving as Project Head - Sales at Kushal Wallstreet
- Qualified Company Secretary with a strong legal and compliance background
The appointment of Ms. Jain is expected to bring valuable insights and expertise to Nath Bio-Genes' board, particularly in areas of compliance and business development.
Nath Bio-Genes' strong Q1 performance sets a positive tone for the fiscal year 2025-26, reflecting the company's resilience and growth potential in the seed industry. Investors and stakeholders will be keenly watching the company's performance in the coming quarters to see if this growth momentum continues.
Historical Stock Returns for Nath Bio-Genes
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.42% | -7.17% | -16.06% | -21.82% | -27.51% | -50.77% |
17
